메뉴 건너뛰기




Volumn 263, Issue 1, 2012, Pages 53-63

Neoadjuvant chemotherapy in breast cancer: Prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging - Prospective assessment

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB; CONTRAST MEDIUM; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

EID: 84861434698     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12111177     Document Type: Article
Times cited : (113)

References (27)
  • 1
    • 77951629946 scopus 로고    scopus 로고
    • Capecitabine in addition to anthracyclineand taxane-based neoadjuvant treatment in patients with primary breast cancer: Phase III GeparQuattro study
    • von Minckwitz G, Rezai M, Loibl S, et al. Capecitabine in addition to anthracyclineand taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010;28(12):2015-2023.
    • (2010) J Clin Oncol , vol.28 , Issue.12 , pp. 2015-2023
    • Von Minckwitz, G.1    Rezai, M.2    Loibl, S.3
  • 2
    • 38349195021 scopus 로고    scopus 로고
    • Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy
    • Jeruss JS, Mittendorf EA, Tucker SL, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2008;26(2):246-252.
    • (2008) J Clin Oncol , vol.26 , Issue.2 , pp. 246-252
    • Jeruss, J.S.1    Mittendorf, E.A.2    Tucker, S.L.3
  • 7
    • 36749069360 scopus 로고    scopus 로고
    • 18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy
    • 18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34(12):1915-1924.
    • (2007) Eur J Nucl Med Mol Imaging , vol.34 , Issue.12 , pp. 1915-1924
    • Berriolo-Riedinger, A.1    Touzery, C.2    Riedinger, J.M.3
  • 8
    • 70350539566 scopus 로고    scopus 로고
    • 18FFDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer
    • Duch J, Fuster D, Muñoz M, et al. 18FFDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009;36(10):1551-1557.
    • (2009) Eur J Nucl Med Mol Imaging , vol.36 , Issue.10 , pp. 1551-1557
    • Duch, J.1    Fuster, D.2    Muñoz, M.3
  • 9
    • 67349209897 scopus 로고    scopus 로고
    • The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
    • Kumar A, Kumar R, Seenu V, et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 2009;19(6):1347-1357.
    • (2009) Eur Radiol , vol.19 , Issue.6 , pp. 1347-1357
    • Kumar, A.1    Kumar, R.2    Seenu, V.3
  • 10
    • 77957356704 scopus 로고    scopus 로고
    • The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: Comparison with ultrasonography and magnetic resonance imaging
    • Choi JH, Lim HI, Lee SK, et al. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging. J Surg Oncol 2010;102(5):392-397.
    • (2010) J Surg Oncol , vol.102 , Issue.5 , pp. 392-397
    • Choi, J.H.1    Lim, H.I.2    Lee, S.K.3
  • 11
    • 50849118098 scopus 로고    scopus 로고
    • Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: Prognostic value as compared with histopathology
    • Emmering J, Krak NC, Van der Hoeven JJ, et al. Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology. Ann Oncol 2008;19(9):1573-1577.
    • (2008) Ann Oncol , vol.19 , Issue.9 , pp. 1573-1577
    • Emmering, J.1    Krak, N.C.2    Van Der Hoeven, J.J.3
  • 12
    • 74649084527 scopus 로고    scopus 로고
    • Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy
    • Jung SY, Kim SK, Nam BH, et al. Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol 2010;17(1):247-253.
    • (2010) Ann Surg Oncol , vol.17 , Issue.1 , pp. 247-253
    • Jung, S.Y.1    Kim, S.K.2    Nam, B.H.3
  • 13
    • 18844386580 scopus 로고    scopus 로고
    • Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy
    • DOI 10.1007/s10549-004-5819-2
    • Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005;91(1):1-10. (Pubitemid 40684933)
    • (2005) Breast Cancer Research and Treatment , vol.91 , Issue.1 , pp. 1-10
    • Pickles, M.D.1    Lowry, M.2    Manton, D.J.3    Gibbs, P.4    Turnbull, L.W.5
  • 14
    • 33646148970 scopus 로고    scopus 로고
    • Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: Initial clinical results
    • Padhani AR, Hayes C, Assersohn L, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006;239(2):361-374.
    • (2006) Radiology , vol.239 , Issue.2 , pp. 361-374
    • Padhani, A.R.1    Hayes, C.2    Assersohn, L.3
  • 15
    • 58149198586 scopus 로고    scopus 로고
    • Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer
    • Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008;14(20):6580-6589.
    • (2008) Clin Cancer Res , vol.14 , Issue.20 , pp. 6580-6589
    • Ah-See, M.L.1    Makris, A.2    Taylor, N.J.3
  • 17
    • 66749184675 scopus 로고    scopus 로고
    • Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI
    • Johansen R, Jensen LR, Rydland J, et al. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Reson Imaging 2009;29(6):1300-1307.
    • (2009) J Magn Reson Imaging , vol.29 , Issue.6 , pp. 1300-1307
    • Johansen, R.1    Jensen, L.R.2    Rydland, J.3
  • 19
    • 78349273661 scopus 로고    scopus 로고
    • Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer
    • Partridge SC, Vanantwerp RK, Doot RK, et al. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. J Magn Reson Imaging 2010;32(5):1124-1131.
    • (2010) J Magn Reson Imaging , vol.32 , Issue.5 , pp. 1124-1131
    • Partridge, S.C.1    Vanantwerp, R.K.2    Doot, R.K.3
  • 21
    • 77954534879 scopus 로고    scopus 로고
    • Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: Synopsis of Version 1.0
    • Fukukita H, Senda M, Terauchi T, et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0. Ann Nucl Med 2010;24(4):325-334.
    • (2010) Ann Nucl Med , vol.24 , Issue.4 , pp. 325-334
    • Fukukita, H.1    Senda, M.2    Terauchi, T.3
  • 22
    • 66149139452 scopus 로고    scopus 로고
    • From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors
    • Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122S-150S.
    • (2009) J Nucl Med , vol.50 , Issue.SUPPL. 1
    • Wahl, R.L.1    Jacene, H.2    Kasamon, Y.3    Lodge, M.A.4
  • 23
    • 6944235697 scopus 로고    scopus 로고
    • Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: A simulation study
    • Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45(9):1519-1527. (Pubitemid 47618506)
    • (2004) Journal of Nuclear Medicine , vol.45 , Issue.9 , pp. 1519-1527
    • Boellaard, R.1    Krak, N.C.2    Hoekstra, O.S.3    Lammertsma, A.A.4
  • 24
    • 0032757213 scopus 로고    scopus 로고
    • 18F]- fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations
    • DOI 10.1016/S0959-8049(99)00229-4, PII S0959804999002294
    • Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35(13):1773-1782. (Pubitemid 29512308)
    • (1999) European Journal of Cancer , vol.35 , Issue.13 , pp. 1773-1782
    • Young, H.1    Baum, R.2    Cremerius, U.3    Herholz, K.4    Hoekstra, O.5    Lammertsma, A.A.6    Pruim, J.7    Price, P.8
  • 25
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    • Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
    • (2009) Eur J Cancer , vol.45 , Issue.2 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 27
    • 33748741191 scopus 로고    scopus 로고
    • Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration
    • DOI 10.1093/annonc/mdl136
    • Semple SI, Staff RT, Heys SD, et al. Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Ann Oncol 2006;17(9):1393-1398. (Pubitemid 44400377)
    • (2006) Annals of Oncology , vol.17 , Issue.9 , pp. 1393-1398
    • Semple, S.I.K.1    Staff, R.T.2    Heys, S.D.3    Redpath, T.W.4    Welch, A.E.5    Ahearn, T.S.6    Hutcheon, A.W.7    Gilbert, F.J.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.